Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284174 | 0.98 | TSHR (0.54) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL1799910 | 0.95 | TSHR (0.44) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL284797 | 0.90 | TSHR (0.42) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL5792196 | 0.89 | TSHR (0.47) | TSHRALDH1A1CYP3A4HPGDNAAA | |
| SCHEMBL1603365 | 0.89 | TSHR (0.52) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL9715428 | 0.89 | TSHR (0.40) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL4113049 | 0.89 | TSHR (0.40) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL10519867 | 0.88 | NAAA (0.52) | TSHRALDH1A1CYP3A4HPGDATM | |
| SCHEMBL3666982 | 0.88 | NAAA (0.52) | TSHRALDH1A1CYP3A4HPGDATM | |
| SCHEMBL18864334 | 0.88 | NAAA (0.52) | TSHRALDH1A1CYP3A4HPGDATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10668676-B2 | Ophthalmic devices | BAUSCH & LOMB INCORPORATED (US) | 2020-06-02 | — | — | US | claimed |
| US-20200047437-A1 | OPHTHALMIC DEVICES | MEDICIS PHARMACEUTICAL CORPORATION | 2020-02-13 | — | — | US | claimed |
| EP-3091050-B1 | THIOL-ENE POLYMERIZATION WITH VINYLESTERS AND VINYLCARBONATE | SYNTHES GMBH (CH) | 2018-07-18 | — | — | EP | claimed |
| US-9814801-B2 | Thiol-ene polymerization with vinylesters and vinylcarbonate | DePuy Synthes Products, Inc. (US) | 2017-11-14 | — | — | US | claimed |
| EP-3091050-A1 | THIOL-ENE POLYMERIZATION WITH VINYLESTERS AND VINYLCARBONATE | Synthes GmbH (CH) | 2016-11-09 | — | — | EP | claimed |
| US-20160243279-A1 | THIOL-ENE POLYMERIZATION WITH VINYLESTERS AND VINYLCARBONATE | SYNTHES GMBH (CH) | 2016-08-25 | — | — | US | claimed |
| EP-2764049-B1 | THIOL-ENE POLYMERIZATION WITH VINYLESTERS AND VINYLCARBONATE | SYNTHES GMBH (CH) | 2016-08-17 | — | — | EP | claimed |
| US-8999323-B2 | Composition that can be cured by polymerisation for the production of biodegradable, biocompatible, cross-linkable polymers on the basis of polyvinyl alcohol | TECHNISCHE UNIVERSITÄT WIEN (AT) | 2015-04-07 | — | — | US | claimed |
| EP-2428235-B1 | Use of compounds hardened by means of polymerisation for producing biodegradable, biocompatible, networked polymers | UNIV WIEN TECH (AT) | 2014-06-04 | — | — | EP | claimed |
| US-20130084543-A1 | THIOL-ENE POLYMERIZATION WITH VINYLESTERS AND VINYLCARBONATE | TECHNISCHE UNIVERSITAT WIEN (AT) | 2013-04-04 | — | — | US | claimed |
| EP-2428235-A2 | Use of compounds hardened by means of polymerisation for producing biodegradable, biocompatible, networked polymers | Technische Universität Wien (AT) | 2012-03-14 | — | — | EP | claimed |
| US-20100303804-A1 | COMPOSITION THAT CAN BE CURED BY POLYMERISATION FOR THE PRODUCTION OF BIODEGRADABLE, BIOCOMPATIBLE, CROSS-LINKABLE POLYMERS ON THE BASIS OF POLYVINYL ALCOHOL | TECHNISCHE UNIVERSITAT WIEN (AT) | 2010-12-02 | — | — | US | claimed |
| US-6261813-B1 | ACYLATING PACLITAXEL WITH BIFUNCTIONAL ACYL DONOR USING HYDROLASE TO FORM ACTIVATED ACYL ESTER OR CARBONATE, THEN ACYLATING NUCLEOPHILE WITH ACTIVATED ESTER OR CARBONATE IN PRESENCE OF HYDROLASE; IMPROVED WATER SOLUBILITY | ALBANY MOLECULAR RESEARCH, INC. | 2001-07-17 | — | — | US | claimed |
| US-11897985-B2 | Water extractable ophthalmic devices | BAUSCH & LOMB INCORPORATED (US) | 2024-02-13 | — | — | US | disclosed |
| US-11873361-B2 | Ophthalmic devices | BAUSCH + LOMB IRELAND LIMITED (IE) | 2024-01-16 | — | — | US | disclosed |
| US-20230089707-A1 | OPHTHALMIC DEVICES | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2023-03-23 | — | — | US | disclosed |
| WO-2009065162-A2 | COMPOSITION THAT CAN BE CURED BY POLYMERISATION FOR THE PRODUCTION OF BIODEGRADABLE, BIOCOMPATIBLE, CROSS-LINKABLE POLYMERS ON THE BASIS OF POLYVINYL ALCOHOL | TECHNISCHE UNIVERSITÄT WIEN (AT) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009065162-A2 | COMPOSITION THAT CAN BE CURED BY POLYMERISATION FOR THE PRODUCTION OF BIODEGRADABLE, BIOCOMPATIBLE, CROSS-LINKABLE POLYMERS ON THE BASIS OF POLYVINYL ALCOHOL | TECHNISCHE UNIVERSITÄT WIEN (AT) | 2009-05-28 | — | — | WO | disclosed |
| US-20090047717-A1 | ENZYME-CATALYZED POLYCARBONATE AND POLYCARBONATE ESTER SYNTHESIS | SyntheZyme, LLC | 2009-02-19 | — | — | US | disclosed |
| US-6261813-B1 | ACYLATING PACLITAXEL WITH BIFUNCTIONAL ACYL DONOR USING HYDROLASE TO FORM ACTIVATED ACYL ESTER OR CARBONATE, THEN ACYLATING NUCLEOPHILE WITH ACTIVATED ESTER OR CARBONATE IN PRESENCE OF HYDROLASE; IMPROVED WATER SOLUBILITY | ALBANY MOLECULAR RESEARCH, INC. | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130084543-A1 | THIOL-ENE POLYMERIZATION WITH VINYLESTERS AND VINYLCARBONATE | TMT1A, MGMT, CBS | TSHR 2137/4885ALDH1A1 335/4885CYP3A4 1082/4885 |
| US-20100303804-A1 | COMPOSITION THAT CAN BE CURED BY POLYMERISATION FOR THE PRODUCTION OF BIODEGRADABLE, BIOCOMPATIBLE, CROSS-LINKABLE POLYMERS ON THE BASIS OF POLYVINYL ALCOHOL | SCO2, CBR1, CBR3 | TSHR 4555/4885ALDH1A1 822/4885CYP3A4 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.